期刊文献+

两种人乳头状瘤病毒检测方法的比较

Comparison of Real-time PCR and Flow Through Hybridization for HPV Detection
下载PDF
导出
摘要 目的评价导流杂交和实时荧光定量(real-time)PCR对宫颈癌患者HPV感染检测的临床意义。方法采用导流杂交和real-time PCR分别对190例患者进行HPV感染检测,并对检测结果进行分析。结果在190例检测标本中,导流杂交法检测出113例HPV阳性,阳性检出率为59.5%,筛查宫颈癌的敏感度为58.1%,特异度为39.2%,阳性预测值为47.8%,阴性预测值为49.4%。real-time PCR检测出106例阳性,阳性检出率为55.8%,筛查宫颈癌的敏感度为54.8%,特异度为43.3%,阳性预测值为48.1%,阴性预测值为50.0%。导流杂交和real-time PCR检出的HPV阳性率差异无统计学意义,而且一致性检验显示两种方法具有较高的一致性(符合率为87.9%)。结论本研究结果表明,导流杂交和real-time PCR方法检测HPV未表现出较大的差异,在宫颈癌筛查中可以将两种方法结合使用,以提高检测的准确性,降低漏诊率。 Objective To evaluate the clinic value of flow through hybridization and real-time PCR in detecting HPV of cervical carcinoma.Methods 190 cases of HPV of cervical carcinoma were detected by using flow through hybridization and real-time PCR,respectively.Results There were 113 positive cases (59.5%)detected with flow through hybridization,and the sensitivity,specificity,positive-predictive value and negativepredictive value in detecting HPV for cervical carcinoma were 58.1%,39.2%,47.8% and 49.4% respectively.There were 106 positive cases (55.8%) detected with real-time PCR,and the sensitivity,specificity,positive-predictive value and negative-predictive value in detecting HPV for cervical carcinoma were 54.8%,43.3%,48.1% and 50.0% respectively.There was a concordance rate of 87.9% in the detection of HPV between two methods.Conclusion The results of this study suggest that there are no significant differences in the detection of HPV between flow through hybridization and real-time PCR.The detective rate may be improved in screening cervical carcinoma by combination of the two methods.
出处 《标记免疫分析与临床》 CAS 2014年第3期298-300,共3页 Labeled Immunoassays and Clinical Medicine
关键词 人乳头瘤病毒 导流杂交 REAL-TIME PCR 宫颈癌 Human papillomavirus Flow through hybridization Real-time PCR Cervical carcinoma
  • 相关文献

参考文献12

  • 1Valdespino V M, Valdespino V E. Cervical cancer screening: state of the art. Curt Opin Obstet Gynecol, 2006, 18( 1 ) :35-40.
  • 2Scheurer M E, Tortolero- Luna G , Adler- Storthz K. Human papillomavirus infection : biology, epidemiology, and prevention. Int J Gynecol Cancer,2005,15 (5) :727-746.
  • 3Van Doorslaer K, Bernard H U, Chen Z, et al. Papillomaviruses: evolution, Linnaean taxonomy and current nomenclature. Trends Microbio1,2011,19 (2) :49-50.
  • 4Parkin D M, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globoean 2000. Int J Cancer,2001,94(2) :153-156.
  • 5Arbyn M, Sankaranarayanan R, Muwonge R, et al. Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer,2008,123 (1): 153-160.
  • 6Almonte M, Ferreceio C, Gonzales M, et al. Risk factors for high- risk human papilloma-virus infection and cofactors for high-grade cervical disease in Peru. Int J Gynecol Cancer,2011,21 (9) :1654- 1663.
  • 7Koshiol J, Limlsay L, Pimenta J M, et al. Persistent human papillomavirus infection and cervical neoplasia:a systematic review and meta-analysis. Am J Epidemiol, 2008, 168 (2) : 123-137.
  • 8Zhao F H, Lin M J, Chen F, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol, 2010, 11 (12) :1160-1171.
  • 9南京柱,李秀娟,杨秀,童红莉,李海潮,田亚平.6319例高危型人乳头瘤病毒核糖核酸定量检测的结果分析[J].标记免疫分析与临床,2012,19(2):74-77. 被引量:6
  • 10Li Y, Wang Y, Jia C, et al. Detection of human papillomavirus genotypes with liquid bead microarray in cervical lesions of northern Chinese patients. Cancer Genet Cytogenet, 2008, 182 (1) :12-17.

二级参考文献23

  • 1Sankaranarayanan R,Esmy PO,Rajkumar R,et al.Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu,India:a cluster randomised trial.Lancet,2007,370:398-406.
  • 2Marc Arbyn.Sankaranarayanan R.Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven stujies in Africa and India.Int J Cancer,2008,123:153-160.
  • 3Li N,Ma CP,Sun LX,et al.Evaluation on the visual inspection with Lugol's iodine in cervical cancer screening program.Chin J Epidemio,2006,27:15-18.
  • 4Qiao YL,Zhang WH,Li L,et al.The cross sectional comparative study of cervical cancer screening methods.Acta Acad Med Sin,2002,24:50-53.
  • 5Arbyn M,Sasieni P,Meijer CJLM,et al.Chapter 9:clinical applications of HPV testing:a summary of meta-analyses.Vaccine,2006,24:78-89.
  • 6Goldie SJ,Kim JJ,Wright TC.Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more.Obstet Gynecol,2004,103:617-618.
  • 7Cronjé HS,Parham GP,Cooreman BF,et al.A comparison of four screening methods for cervical neoplasia in a developing country.Am J Obstet Gynecol,2003,188:395-400.
  • 8Wu S,Meng L,Wang S,et al.A comparison of four screening methods for cervical neoplasia.Int J Gynaecol Obstet,2005,91:189-193.
  • 9Almonte M,Ferreccio C,Winkler JL,et al.Cervical screening by visual inspection,HPV testing,liquid-based and conventional cytology in Amazonian Peru.Int J Cancer,2007,121:796-802.
  • 10Sankaranarayanan R,Wesley R,Thara S,et al.Test characteristics of visual inspection with 4% acetic acid (VIA) and Lugol's iodine (VILI) in cervical cancer screening in Kerala,India.Int J Cancer,2003,106:404-408.

共引文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部